Supporting evidence

• LedgerRecord Q4 revenue of $1.5 billion and FY2026 revenue of $5.7 billion, both growing 9-10% year-over-year
• LedgerSolid quarter based on: Record Q4 revenue of $1.5 billion and FY2026 revenue of $5.7 billion, both growing 9-10% year-over-year · Non-GAAP EPS growth of 16% in Q4 and 17% for the full year, supported…
• LedgerRevenue +8% YoY (Q4 FY2026)

• EventRecord Quarterly Revenue
• EventNon-GAAP EPS Growth +16% Q4 / +17% FY
• EventShareholder Returns Guidance Raised >$1.85B FY2027
• EventEnhances Resmed's reach in sleep health education and care pathways.
• EventDemonstrates strong commitment to shareholder returns and financial health.
• EventIndicates continued strong shareholder return policy for the next fiscal year.
• InitiativeThe sale of MatrixCare is a direct action taken to align with this strategy, indicating active progress.
• EventCurrency headwinds reducing constant currency growth advantage — 8% vs. reported 9-10% gap signals FX exposure across Europe, Asia, and Latin America geographies
• EventIntegration and execution risk from Noctrix Health acquisition in the nascent RLS wearable therapeutics market, an unproven commercial category for ResMed